Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Myelodysplastic syndromes.

D C Doll, A F List

    The Western Journal of Medicine
    |August 1, 1989
    PubMed
    Summary
    This summary is machine-generated.

    Myelodysplastic syndromes are stem cell disorders with ineffective blood cell production and a risk of leukemia. Prognostic factors are known, but causes and standard treatments remain unclear, necessitating new therapeutic strategies.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    RAS-pathway mutations are common in patients with ruxolitinib refractory/intolerant myelofibrosis: molecular analysis of the PAC203 cohort.

    Leukemia·2023
    Same author

    Intrapatient functional clonality deconvoluted by coupling intracellular flow cytometry and next-generation sequencing in human leukemia.

    Leukemia·2017
    Same author

    Molecular predictors of response in patients with myeloid neoplasms treated with lenalidomide.

    Leukemia·2016
    Same author

    Extended survival and reduced risk of AML progression in erythroid-responsive lenalidomide-treated patients with lower-risk del(5q) MDS.

    Leukemia·2015
    Same author

    Short- and long-term benefits of lenalidomide treatment in patients with lower-risk del(5q) myelodysplastic syndromes.

    Annals of oncology : official journal of the European Society for Medical Oncology·2015
    Same author

    An international data set for CMML validates prognostic scoring systems and demonstrates a need for novel prognostication strategies.

    Blood cancer journal·2015
    Same journal

    Does daily use of sunscreen or beta-carotene supplements prevent skin cancer in healthy adults?

    The Western journal of medicine·2008
    Same journal

    [Not Available].

    The Western journal of medicine·2008
    Same journal

    [Not Available].

    The Western journal of medicine·2008
    Same journal

    [Not Available].

    The Western journal of medicine·2008
    Same journal

    [Not Available].

    The Western journal of medicine·2008
    Same journal

    [Not Available].

    The Western journal of medicine·2008
    See all related articles

    Area of Science:

    • Hematology
    • Oncology
    • Stem Cell Biology

    Background:

    • Myelodysplastic syndromes (MDS) are a diverse group of hematopoietic stem cell disorders.
    • Characterized by ineffective blood cell production (hematopoiesis) and a risk of progressing to acute leukemia.
    • The natural course of MDS is variable, influenced by several prognostic factors.

    Purpose of the Study:

    • To review the characteristics of myelodysplastic syndromes.
    • To discuss prognostic indicators in MDS.
    • To highlight the need for novel therapeutic approaches due to the lack of standard treatment.

    Main Methods:

    • Review of existing literature on myelodysplastic syndromes.
    • Analysis of prognostic factors such as French-American-British classification and karyotype.

    Related Experiment Videos

  • Discussion of potential pathogenetic mechanisms, including oncogene alterations.

    • Main Results:

    • Identified key prognostic factors influencing MDS outcomes.
    • Highlighted the unknown pathogenesis of MDS, with potential links to oncogene mutations.
    • Emphasized the absence of a universally accepted standard therapy for MDS.

    Conclusions:

    • Myelodysplastic syndromes require further research into their pathogenesis.
    • Prognostic assessment is crucial for managing patients with MDS.
    • Development of novel treatment strategies is essential for improving patient outcomes.